Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiki Arita

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Optics Express|July 13, 2011
Continuously tunable slow-light device consisting of heater-controlled silicon microring arrayFumihiro Shinobu, Norihiro Ishikura, Yoshiki Arita, et al.
Cancer Medicine|August 27, 2024
Risk factors for lenvatinib-induced palmar-plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective studyShusuke Uekusa, Maho Nemoto, Yuki Hanai, et al.
British Journal of Clinical Pharmacology|November 21, 2024
Risk factors for lenvatinib-induced hypertension in patients with hepatocellular carcinoma: A retrospective studyShusuke Uekusa, Misaki Nakashin, Yuki Hanai, et al.
Pharmacology|August 17, 2023
Risk Factors for Lenvatinib-Induced High-Grade Hypothyroidism in Patients with Hepatocellular Carcinoma: A Retrospective StudyShusuke Uekusa, Maho Nemoto, Yuki Hanai, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Optics Express|July 13, 2011
Continuously tunable slow-light device consisting of heater-controlled silicon microring arrayFumihiro Shinobu, Norihiro Ishikura, Yoshiki Arita, et al.
Cancer Medicine|August 27, 2024
Risk factors for lenvatinib-induced palmar-plantar erythrodysesthesia syndrome in patients with hepatocellular carcinoma: A retrospective studyShusuke Uekusa, Maho Nemoto, Yuki Hanai, et al.
British Journal of Clinical Pharmacology|November 21, 2024
Risk factors for lenvatinib-induced hypertension in patients with hepatocellular carcinoma: A retrospective studyShusuke Uekusa, Misaki Nakashin, Yuki Hanai, et al.
Pharmacology|August 17, 2023
Risk Factors for Lenvatinib-Induced High-Grade Hypothyroidism in Patients with Hepatocellular Carcinoma: A Retrospective StudyShusuke Uekusa, Maho Nemoto, Yuki Hanai, et al.
Pageof 1